Clinical trial

A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol

NCT01817452

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Trastuzumab Normalized identity: trastuzumabView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Pertuzumab Normalized identity: pertuzumabView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Paclitaxel Normalized identity: paclitaxelView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2014-03-01

PhasePHASE2

Conditions

Breast Cancerverified · MONDO: breast cancer

Interventions

TrastuzumabDRUG · verified · RxNorm: trastuzumab

PertuzumabDRUG · verified · RxNorm: pertuzumab

PaclitaxelDRUG · verified · RxNorm: paclitaxel

Sponsors & collaborators

Women's Cancer Study Group GmbHlead sponsor

Roche Pharma AGcollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01817452 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.